Publication Category: Oncology Publications

List categories

Precision Oncology
Early Cancer Detection

A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring

In this study, we validated a new hybrid capture-based sequencing (HYB) workflow, a versatile approach that enables both tumor-informed and tumor-naïve liquid biopsy profiling. This methodology provides a streamlined, scalable solution for comprehensive liquid biopsy profiling and longitudinal measurable residual disease (MRD) monitoring in routine clinical practice.

Journal:

  • The Journal of Liquid Biopsy

Publication date:

  • September 19, 2026

Authors:

  • Tu Nguyen, Son-Nam H. Le, Van-Anh Nguyen Hoang, Quang Thinh Trac, Cang Huynh, Vy Nguyen, Thien-Phuc Nguyen Hoang, Nhat-Anh Dao Minh, Tran Binh Nguyen, Hoai-Nghia Nguyen, Nam H. B. Tran, and Lan N. Tu

Test:

  • K-TRACK, K-TRACK BO

Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors

The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.

Journal:

  • Therapeutic Advances in Medical Oncology

Publication date:

  • November 18, 2025

Authors:

  • Tu Nguyen, Van-Anh Nguyen Hoang, Trong Hieu Nguyen, Trung Hieu Tran, Ngoc Nguyen, Tho Thi Le Vo, Duy Sinh Nguyen, Hoa Giang, Hoai-Nghia Nguyen, and Lan N. Tu

Test:

  • K-TRACK, K-TRACK BO

Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights

Comprehensive genomic profiling (CGP) is a time- and tissue- efficient method to help guide precision oncology. To enhance the clinical utility of CGP, we investigated the performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring. Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA-only CGP. The integration of ctDNA detection further helped detect tumor-agnostic mutations and monitor treatment response.

Journal:

  • Cancer Medicine

Publication date:

  • December 8, 2025

Authors:

  • Nam H. B. Tran, Thien-Phuc Hoang Nguyen, Vinh Quang Bui, Vu Thuong Le, Trong Khoa Mai, Van-Anh Nguyen Hoang, Tien Anh Nguyen, Minh-Duc Nguyen, Ha-Hieu Pham, Tho Thi Le Vo, My T. T. Ngo, Du Quyen Nguyen, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Minh-Duy Phan, Hoa Giang, Lan N. Tu

Test:

  • K-4CARE

Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals

Breast cancer (BC) remains the second leading cause of cancer-related mortality among women worldwide. Liquid biopsy based on circulating tumor DNA (ctDNA) offers a promising noninvasive approach for early detection; however, differentiating malignant tumors from benign abnormalities remains a significant challenge.

Journal:

  • BMC Biology

Publication date:

  • August 20, 2025

Authors:

  • Thi Tuong Vi Van, Trung Hieu Tran, Thi Hue Hanh Nguyen, Van Thien Chi Nguyen, Dac Ho Vo, Giang Thi Huong Nguyen, Trong Hieu Nguyen, Kim Sang To, Anh Luan Nguyen, Cao Hong An Tran, Thanh Xuan Jasmine, Thi Loan Vo, Thi Huong Thoang Nai, Thuy Trang Tran, My Hoang Truong, Ngan Chau Tran, Thi Loc Le, Thi Hong Nhung Nguyen, Ngoc Hieu Tu, Thanh Son Tran, Bao Toan Le, Van Phong Tang, Pham Thanh Nhan Nguyen, Khac Tien Nguyen, Van Chien Ho, Xuan Vinh Nguyen, Nhu Nhat Tan Doan, Thi Trang Tran, Thi Minh Thu Tran, Vu Uyen Tran, Minh Phong Le, Thi Luyen Vu, Ba Linh Tieu, Huu Tam Phuc Nguyen, Luu Hong Dang Nguyen, Ngoc Minh Phan, Thi Van Phan, Thi Thanh Thuy Do, Thi Huyen Dao, Hung Sang Tang, Duy Sinh Nguyen, Hoa Giang, Minh Duy Phan, Hoai-Nghia Nguyen, Duc Hieu Vo & Le Son Tran

Test:

  • SPOT-MAS
Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency (HRD) in ovarian cancer

Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer

We developed an assay to accurately determine the homologous recombination deficiency status of ovarian tissue samples, including those with low DNA quality. This study was the first to analyze the prevalence and spectrum of homologous recombination deficiency in Vietnamese patients with ovarian cancer. Comprehensive assessment of homologous recombination deficiency should be performed instead of BRCA1/2 testing alone so that no patients miss their opportunity for PARPi treatment.

Journal:

  • Frontier

Publication date:

  • September 1, 2025

Authors:

  • Thien-Phuc Nguyen Hoang , Nam H. B. Tran , Tien Anh Nguyen, My T. T. Ngo, Anh Duong Doan, Du Quyen Nguyen, Hung Sang Tang, Duy Sinh Nguyen, Cam Tu Nguyen Thi, Thanh Thuy Do Thi , Hoai-Nghia Nguyen, Hoa Giang and Lan N. Tu

Test:

  • K-4CARE, HRD Insight

Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer

The clinical utilization of circulating tumor DNA (ctDNA) in breast cancer (BC) management is not well-defined. In this prospective study, 168 patients with early-stage BC were recruited, serial blood samples were collected before and after surgery. Tumor-informed ctDNA testing was performed, which sequenced tumors for 95 genes followed by bespoke mPCR to track 1–9 mutations in the plasma. ctDNA was detected before surgery in 14.6%, 40.0%, 83.8%, and 80.0% of HR+ low-risk, HR+ high-risk, HR-HER2+ and HR-HER2- patients, respectively. Pre-operative ctDNA positivity was significantly associated with decreased disease-free survival (DFS) (adjusted HR = 3.09, 95% CI 2.65–80.0, p = 0.001). After a median 26.6-month follow-up, 11 patients relapsed, and ctDNA at landmark time point 2–4 weeks after surgery was detected in 50.0% (5/10) of cases. Landmark ctDNA clearance was associated with significantly longer DFS (p = 0.0009) and positive ctDNA persistence after adjuvant therapy occurred in 36.4% (4/11) of stage-III patients. During surveillance, ctDNA detection had 90.9% sensitivity and 98.8% specificity to predict recurrence, and median lead time of 9.7 months. Patients with detected ctDNA had shorter DFS than those with undetectable ctDNA (adjusted HR = 207.05, 95% CI 41.38- > 1000, p = 0.001). Therefore, ctDNA status both before and after surgery could help stratify recurrence risk for BC patients.

Journal:

  • npj Breast Cancer

Publication date:

  • June 20, 2025

Authors:

  • Sao Trung Nguyen, Van-Anh Nguyen Hoang, Vu Nguyen Trieu, Thanh Huyen Pham, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Nguyen, Dao Nguyen Vinh, Thanh Thuy Thi Do, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Hoa Giang & Lan N. Tu

Test:

  • K-TRACK

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors

In the early-stage I-III, preoperative ctDNA detection rates were 66.7%, 84.6%, 54.3%, 52.6%, 93.3%, and 75.0% for lung, colorectal, breast, gastric, liver, and ovarian cancers, respectively. After surgery, 84.4% (38/45) of patients with recurrence had ctDNA detected in the plasma, while 96.3% (210/218) of patients with no recurrence had negative results. Postoperative ctDNA positivity significantly increased the risk of recurrence (P 100 [95% CI, 26.9 to >100.0) cancers. In the metastatic stage IV, pretreatment ctDNA detection rates were 80.0%, 87.7%, 73.3%, 70.6%, 91.7%, and 81.8% for lung, colorectal, breast, gastric, liver, and ovarian cancers, respectively. Case studies were presented to demonstrate utilization of ctDNA at all cancer stages.

Journal:

  • JCO Oncology Advances

Publication date:

  • March 7, 2025

Authors:

  • Van-Anh Nguyen Hoang, MSc; Ngoc Nguyen, BSc; Duc Nhan Le, MD, MSc; Van Son Nguyen, MD; Huong Giang Nguyen Thi, MD; Hong Thang Vu, MD, PhD; Huu Hao Ho, MD; Hong Minh Le, MD, PhD; Tien Dung Nguyen, MD; Huu Nhan Vo, MD, MSc; Thu Suong Le Thi, MD; Van Tuan Ha, MD; Hoang Duong Nguyen, MD; Minh Phuong Nguyen Thi, MD, PhD; Kim Phuong Tran Thi, MD, PhD; Tran Doanh Vi, MD, PhD; Minh Tu Hoang, MD, MSc; Hoang Giang Vu, BSc; Tu Nguyen, MSc; Van T. Phan, MSc; Nguyen Huu Tam Phuc, BSc; Duy Sinh Nguyen, MD, PhD; Hoai-Nghia Nguyen, PhD; and Lan N. Tu, PhD

Test:

  • K-TRACK

Cost-effective shallow genome-wide sequencing for profiling plasma cfDNA signatures to enhance lung cancer detection

Lung cancer (LC) screening via low-dose computed tomography (LDCT) faces challenges including high false-positive rates and low patient compliance. Circulating tumor DNA (ctDNA)-based tests offer a minimally invasive alternative but are limited by high costs and low sensitivity, particularly in early-stage detection. This study introduces a cost-effective, shallow genome-wide sequencing approach for LC detection by profiling multiple cell-free DNA (cfDNA) signatures.

Journal:

  • Future Oncology

Publication date:

  • March 25, 2025

Authors:

  • Van Thien Chi Nguyen,Dac Ho Vo,Thi Trang Tran,Thanh Truong Tran,Thi Hue Hanh Nguyen,Truong Dang Huy Vo,Thi Tuong Vi Van,Thi Luyen Vu,Minh Quang Lam,Giang Thi Huong Nguyen,Trung Hieu Tran,Ngoc Tan Pham,Quang Thinh Trac,Trong Hieu Nguyen,Thi Van Phan,Thi Huyen Dao,Huu Tam Phuc Nguyen,Luu Hong Dang Nguyen,Duy Sinh Nguyen,Hung Sang Tang,Hoa Giang,Minh Duy Phan,Hoai-Nghia Nguyen & Le Son Tran

Test:

  • SPOT-MAS

Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults

Non-invasive multi-cancer early detection (MCED) tests have shown promise in enhancing early cancer detection. However, their clinical utility across diverse populations remains underexplored, limiting their routine implementation. This study aims to validate the clinical utility of a multimodal non-invasive circulating tumor DNA (ctDNA)-based MCED test, SPOT-MAS (Screening for the Presence Of Tumor by DNA Methylation And Size).

Journal:

  • BMC Medicine

Publication date:

  • February 14, 2025

Authors:

  • Luu Hong Dang Nguyen, Thi Hue Hanh Nguyen, Van Hoi Le, Vinh Quang Bui, Lan Hieu Nguyen, Nhu Hiep Pham, Thanh Hai Phan, Huu Thinh Nguyen, Van Song Tran, Chi Viet Bui, Van Kha Vo, Pham Thanh Nhan Nguyen, Ha Huu Phuoc Dang, Van Dung Pham, Van Thinh Cao, Ngoc Minh Phan, Ba Linh Tieu, Giang Thi Huong Nguyen, Dac Ho Vo, Trung Hieu Tran, Thanh Dat Nguyen, Van Thien Chi Nguyen, Trong Hieu Nguyen, Vu Uyen Tran, …Le Son Tran

Test:

  • SPOT-MAS

Combination of Hotspot Mutations With Methylation and Fragmentomic Profiles to Enhance Multi-Cancer Early Detection

Multi-cancer early detection (MCED) through a single blood test significantly advances cancer diagnosis. However, most MCED tests rely on a single type of biomarkers, leading to limited sensitivity, particularly for early-stage cancers. We previously developed SPOT-MAS, a multimodal ctDNA-based assay analyzing methylation and fragmentomic profiles to detect five common cancers. Despite its potential, SPOT-MAS exhibited moderate sensitivities for early-stage cancers. This study investigated whether integrating hotspot mutations into SPOT-MAS could enhance its detection rates.

Journal:

  • Cancer Medicine

Publication date:

  • January 3, 2025

Authors:

  • Thi Hue Hanh Nguyen, Giang Hoang Vu, Tu Thi Nguyen, Tuan Anh Nguyen, Vu Uyen Tran, Luyen Thi Vu, Giang Thi Huong Nguyen, Nhat Duy Nguyen, Trung Hieu Tran, Van Thien Chi Nguyen, Thanh Dat Nguyen, Trong Hieu Nguyen, Dac Ho Vo, Thi Tuong Vi Van, Thanh Thi Do, Minh Phong Le, Le Anh Khoa Huynh, Duy Sinh Nguyen, Hung Sang Tang, Hoai-Nghia Nguyen, Minh-Duy Phan, Hoa Giang, Lan N. Tu, Le Son Tran

Test:

  • SPOT-MAS

Discover More

Reproductive Health Publications​

Oncology Publications

Genetic Diseases Publications

Posters/Abstracts